◎ Sugi Atlas

Atlas / Disease / Lichen planus

Lichen planus

disease
On this page

Also known as lichen ruber planus

Summary

Lichen planus (MONDO:0006572) is a disease (an umbrella term covering 11 Mondo subtypes) with 34 GWAS associations across 10 studies and 37 clinical trials. Top therapeutic interventions include acitretin, alefacept, and alitretinoin. A subtype of dermatitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Umbrella term: 11 Mondo subtypes
  • GWAS associations: 34
  • Clinical trials: 37

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namelichen planus
Mondo IDMONDO:0006572
EFOEFO:1000726
MeSHD008010
DOIDDOID:9201
ICD-10-CML43
ICD-111402978031
NCITC3189
SNOMED CT4776004
UMLSC0023646
MedGen9753
Is cancer (heuristic)no

Also known as: lichen ruber planus

Data availability: 34 GWAS associations (10 studies).

Disease family

This is a subtype of dermatitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › lichen planus

Related subtypes (32): spongiotic dermatitis, atopic eczema, psoriasis, contact dermatitis, urticaria, acneiform dermatitis, acrodermatitis, folliculitis, granuloma annulare, granulomatous dermatitis, neurodermatitis, neurotic excoriation, parapsoriasis, pityriasis rosea, seborrheic dermatitis, acanthosis nigricans, dermatosis papulosa nigra, lichen sclerosus et atrophicus, vitiligo, acne, porphyria cutanea tarda, dermatomyositis, acute generalized exanthematous pustulosis, hydroa vacciniforme, autoimmune bullous skin disease, cutaneous vasculitis, skin infection, intertrigo, lipodermatosclerosis, exfoliative dermatitis, radiodermatitis, food dermatitis

Subtypes (11): lichen planus, familial, linear lichen planus, actinic lichen planus, annular atrophic lichen planus, annular lichen planus, atrophic lichen planus, lichen planus pigmentosus, lichen planus pemphigoides, bullous lichen planus, hypertrophic lichen planus, lichen planus, oral

Genetics & variants

GWAS landscape

34 GWAS associations across 10 studies. Top hits map to 20 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs285928598e-211HLA-DQA1 - HLA-DQB1?0.53
rs94598533e-21CEP43?0.14
rs20938166e-18LINC02341?0.13
rs67808582e-16LPP?0.12
rs43284412e-11AFG3L1P, AFG3L1P?0.1
rs1937696e-11CLEC16A - HNRNPCP4?0.16
rs353183598e-11IL18RAP - SLC9A4?0.12
rs356679742e-10IFIH1?0.37
rs7486706814e-10TNRC18?0.26
rs21114854e-10FAP - IFIH1?0.09
rs563283394e-10LPP?0.12
rs108610307e-10C12orf42 - LINC02401?
rs28939078e-10LINC02929?0.1
rs1177440813e-09CPVL?0.22
rs13914403e-09TET2-AS1, TET2?0.09
rs38255684e-09ZFP36L1?0.09
rs37555708e-09ST3GAL6-AS1?0.09
rs29276088e-09ERAP2?0.09
rs11928630201e-08RPS3?1.39
rs107456801e-08PLXNC1?0.1
rs26011912e-08IQGAP1?0.08
rs1123013222e-08IKZF3?0.23
rs14326112e-08FOXP1?0.09
rs70963843e-08IL2RA - RPL32P23?0.08
rs671117172e-07RGS14?0.08

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90435153Reeve MP20249,426823,206Oral and non-oral lichen planus show genetic heterogeneity and differential risk for autoimmune disease and oral cancer.
GCST90435151Reeve MP20247,428404,662Oral and non-oral lichen planus show genetic heterogeneity and differential risk for autoimmune disease and oral cancer.
GCST90473940UK Biobank Whole-Genome Sequencing Consortium20252,491455,949Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90080351Backman JD20211,295385,047Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084337Backman JD20211,295385,047Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90727064Kim HI202667443,352Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.
GCST90080350Backman JD2021612387,316Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084336Backman JD2021612387,316Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90727037Kim HI202627343,753Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.
GCST004090Nagao Y2017710Genome-Wide Association Study Identifies Risk Variants for Lichen Planus in Patients With Hepatitis C Virus Infection.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding3
Tier 2: splice/UTR2
Tier 3: regulatory0
Tier 4: intronic/intergenic20

MAF distribution

BucketVariants
common (>=0.05)23
low_freq (0.01-0.05)0
rare (<0.01)0
unknown2

Functional consequences

ConsequenceCount
intron_variant13
intergenic_variant7
missense_variant3
3_prime_UTR_variant1
5_prime_UTR_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs28592859632659295G>A0.05intergenic_variantHLA-DQA1 - HLA-DQB18e-211Tier 4: intronic/intergenic
rs94598536167052286C>A,T0.053_prime_UTR_variantCEP433e-21Tier 2: splice/UTR
rs20938161342471900C>T0.05intergenic_variantLINC023416e-18Tier 4: intronic/intergenic
rs67808583188414322A>G0.05intron_variantLPP2e-16Tier 4: intronic/intergenic
rs43284411689983793G>C,T0.05intron_variantAFG3L1P, AFG3L1P2e-11Tier 4: intronic/intergenic
rs1937691611211968T>A,C,G0.05intron_variantCLEC16A - HNRNPCP46e-11Tier 4: intronic/intergenic
rs353183592102456672T>TATAA,TATAAATAAATAATATATAA,TATAC0.05intergenic_variantIL18RAP - SLC9A48e-11Tier 4: intronic/intergenic
rs356679742162268127T>A,C,G0.05missense_variantIFIH12e-10Tier 1: coding
rs74867068175397122C>Tintron_variantTNRC184e-10Tier 4: intronic/intergenic
rs21114852162254026A>G0.05intergenic_variantFAP - IFIH14e-10Tier 4: intronic/intergenic
rs563283393188682769C>T0.05intron_variantLPP4e-10Tier 4: intronic/intergenic
rs1086103012103499166C>A,G0.05intergenic_variantC12orf42 - LINC024017e-10Tier 4: intronic/intergenic
rs28939071062622599A>C0.05intron_variantLINC029298e-10Tier 4: intronic/intergenic
rs117744081729092663A>G0.05missense_variantCPVL3e-09Tier 1: coding
rs13914404105195804C>G0.05intron_variantTET2-AS1, TET23e-09Tier 4: intronic/intergenic
rs38255681468793871C>G,T0.055_prime_UTR_variantZFP36L14e-09Tier 2: splice/UTR
rs3755570398731659A>C,G,T0.05intron_variantST3GAL6-AS18e-09Tier 4: intronic/intergenic
rs2927608596916728G>A,C,T0.05intron_variantERAP28e-09Tier 4: intronic/intergenic
rs11928630201175411547G>A,Tintergenic_variantRPS31e-08Tier 4: intronic/intergenic
rs107456801294221051A>C,G,T0.05intron_variantPLXNC11e-08Tier 4: intronic/intergenic
rs26011911590392993T>A,C0.05intron_variantIQGAP12e-08Tier 4: intronic/intergenic
rs1123013221739788266C>A,G,T0.05missense_variantIKZF32e-08Tier 1: coding
rs1432611371520527G>T0.05intron_variantFOXP12e-08Tier 4: intronic/intergenic
rs7096384106064675C>G,T0.05intergenic_variantIL2RA - RPL32P233e-08Tier 4: intronic/intergenic
rs671117175177363161A>G,T0.05intron_variantRGS142e-07Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
PimecrolimusPhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Alefacept, Alitretinoin, Apremilast, Baricitinib, Clobetasol Propionate, Dexamethasone, Etanercept, Hexaminolevulinate, Hydroxychloroquine, Lycopene, Mechlorethamine, Prednisolone, Ruxolitinib, Secukinumab, Triamcinolone Acetonide.

Clinical trials & evidence

Clinical trials

Clinical trials: 37.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified27
PHASE28
PHASE41
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03630198PHASE4COMPLETEDPain Outcomes Following Intralesional Corticosteroid Injections
NCT06739551PHASE2NOT_YET_RECRUITINGSystemic Treatment Options for Generalized Lichen Planus
NCT00135733PHASE2TERMINATEDA Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus
NCT00285779PHASE2TERMINATEDUse of Etanercept in the Treatment of Moderate to Severe Lichen Planus
NCT01041625PHASE2UNKNOWNPilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus
NCT01538732PHASE2UNKNOWNLichen Planus Mucosae at USZ, Efficacy of Oral Alitretinoin
NCT02850601PHASE2COMPLETEDDexamethasone Solution for the Treatment of Oral Lichen Planus
NCT03697460PHASE2COMPLETEDTopical Ruxolitinib Lichen Planus
NCT03858634PHASE2COMPLETEDA Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
NCT05030415EARLY_PHASE1COMPLETEDIxekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris
NCT00542373Not specifiedACTIVE_NOT_RECRUITINGWidefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer
NCT05928169Not specifiedRECRUITINGDeterminants of Chronic Inflammatory Skin Disease Trajectories
NCT06451744Not specifiedRECRUITINGCellular and Molecular Biomarkers in Patients With Lichen Planus
NCT06472765Not specifiedENROLLING_BY_INVITATIONVaginal Ecosystem and Network in the United States Study
NCT06599411Not specifiedNOT_YET_RECRUITINGIdentification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
NCT00001601Not specifiedCOMPLETEDEvaluation and Treatment of Oral Soft Tissue Diseases
NCT00341497Not specifiedCOMPLETEDBiomarkers for Oral Cancer
NCT00824889Not specifiedCOMPLETEDExploratory Study of Natural Killer Cells in Human Skin
NCT02261662Not specifiedUNKNOWNOff-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection
NCT02532166Not specifiedUNKNOWNIncidence of Esophageal Lichen Planus in Patients With Known Oral Lichen Planus
NCT02732145Not specifiedCOMPLETEDDiagnostic Accuracy of Three Rings Vulvoscopy for Detection of Vulvar Dermatosis
NCT02737176Not specifiedUNKNOWNTobacco Cessation Intervention Study for Oral Diseases
NCT02761122Not specifiedCOMPLETEDImplication of Human Papillomavirus (HPV) in Lichen Physiopathology in Human (HPVLichen)
NCT02881229Not specifiedTERMINATEDVulvar Mucosal Specialty Clinic Chart Review
NCT03265093Not specifiedCOMPLETEDUse of Injectable Platelet Rich Fibrin in Lichen Planus
NCT03340155Not specifiedUNKNOWNMechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
NCT03796806Not specifiedCOMPLETEDMethods Validation Assessment for Study of Inflammatory Skin Disease
NCT04356014Not specifiedUNKNOWNTelangiectatic Palmoplantar Keratoderma in Systemic and Subacute Lupus Erythematosus
NCT04697563Not specifiedCOMPLETEDLaser Therapy in Women With Lichenoid Disorders
NCT04892381Not specifiedUNKNOWNAssessment of PD-1 and PD-L1Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study
NCT04952961Not specifiedCOMPLETEDEarly Detection of Vulval CAncer Through Self-Examination (EDuCATE): Intervention Study
NCT05396261Not specifiedCOMPLETEDa Flexible Wound Dressing for the Management of Genital Skin Conditions
NCT05761158Not specifiedTERMINATEDStudy of the Characteristics of Pruritus in Patients With Frontal Fibrosing Alopecia or Lichen Planus Pilaris
NCT05787925Not specifiedCOMPLETEDAdjunctive Oral Systemic Vitamin E Therapy on Salivary Nitric Oxide Level in Patients With Erosive Oral Lichen Planus
NCT06021405Not specifiedWITHDRAWNKoebner’s Phenomenon in Psoriasis and Lichen Planus
NCT06327620Not specifiedUNKNOWNTreatment Of Oral Lichen Planus
NCT07570706Not specifiedCOMPLETEDMucosal and Nasal Involvement and Their Correlation With Smell and Taste Functions in Lichen Planus Patients

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
ACITRETIN41
ALEFACEPT41
ALITRETINOIN41
APREMILAST41
ETANERCEPT41
IXEKIZUMAB41
VIXARELIMAB21
CHEMBL377517101

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 23

This page pulls from 23 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardbsnpdoidefogenccgwasgwas_studyhgncicd10cmicd11medgenmeshmimmondomondochildmondoparentncitorphanetsctidumls